-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251

Benzinga·08/27/2026 14:30:05
Listen to the news
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $203 to $251.